Compare SCNI & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCNI | XXII |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 3.3M |
| IPO Year | 2014 | 2011 |
| Metric | SCNI | XXII |
|---|---|---|
| Price | $0.73 | $3.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.7K | 34.4K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,832,530.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $79.56 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $0.67 |
| 52 Week High | $6.18 | $11.37 |
| Indicator | SCNI | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 40.98 |
| Support Level | $0.65 | $3.61 |
| Resistance Level | $0.94 | $6.86 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 12.73 | 5.99 |
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.